Using Metformin to Treat Pulmonary Hypertension in Heart Failure Patients
Official title: Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
Funded at University of California, San Francisco · NIH-10460583 · Data updated 2026-11-12
This study is looking at how the diabetes medication metformin might help older patients with heart failure and high blood pressure in the lungs, especially those with metabolic syndrome, to see if it can improve their heart and lung function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 1, 2018 |
| Project end | February 28, 2026 |
| Funding year | 2022 |
| Award (this year) | $576,734 |
| NIH project number | 5R01AG058659-05 |
| Project ID | NIH-10460583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with heart failure with preserved ejection fraction who also exhibit signs of pulmonary hypertension.
✕Less likely to help
Patients without heart failure or those who do not have pulmonary hypertension may not benefit from this research.
What this research studies
This research investigates the effects of metformin, a common diabetes medication, on patients suffering from pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF). The study aims to better understand the specific characteristics of this patient group, particularly those who are older and may have metabolic syndrome. By examining how metformin influences pulmonary pressures and overall heart function, the research seeks to identify potential new treatment options for this challenging condition. Patients will be closely monitored for changes in their heart and lung function throughout the trial.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option for patients with pulmonary hypertension and heart failure, potentially improving their quality of life and functional capacity.
How similar studies have gone: Previous studies have shown promising results with metformin in heart failure patients, suggesting that this approach may be a viable treatment option.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Simon, Marc a — University of California, San Francisco
- Study coordinator: Simon, Marc a
Related research
Other NIH-funded projects on the same topics.
-
Right heart muscle mechanics in pulmonary hypertension with heart failure
Researchers are studying how the right heart muscle fails in people who have heart failure with reduced ejection fraction and high blood pressure in the lungs, to improve diagnosis and care.
-
Non-invasive, automated heart health checker for early heart failure and pulmonary hypertension
A new non-invasive device platform aims to measure four key heart-hemodynamics (EF, CO, PAP, PCWP) safely at home or in basic clinics to help people at risk of heart failure or pulmonary hypertension.
-
Understanding heart muscle function in patients with heart failure and pulmonary hypertension
This study is looking at how well the right side of the heart works in people with heart failure and high blood pressure in the lungs, especially during exercise, to find out more about problems that doctors might not usually catch, which could help improve how we diagnose and treat these conditions.
-
A non-invasive tool to assess heart function and risk of heart failure.
This study is working on a new, easy-to-use tool that can safely check how well your heart is working without any invasive procedures, making it especially helpful for people at risk of heart failure or pulmonary hypertension.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
-
CD4 T Cells, Schistosoma, and Pulmonary Hypertension: Understanding How Immune Cells Drive Disease
A human-health focused study uses a mouse model and human samples to explore how immune cells and inflammation may contribute to a lung blood vessel disease linked to schistosomiasis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.